cGVHD clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
open to eligible people ages 12 years and up
The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).
San Francisco, California and other locations
Our lead scientists for cGVHD research studies include Jerry Lee.
Last updated: